Twin Capital Management Inc. Purchases 304 Shares of Amgen Inc. $AMGN

Twin Capital Management Inc. raised its position in Amgen Inc. (NASDAQ:AMGN) by 1.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,321 shares of the medical research company’s stock after acquiring an additional 304 shares during the quarter. Twin Capital Management Inc.’s holdings in Amgen were worth $5,674,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brighton Jones LLC boosted its holdings in shares of Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares during the period. Abel Hall LLC bought a new position in shares of Amgen during the first quarter worth approximately $232,000. Trek Financial LLC raised its position in shares of Amgen by 25.2% in the first quarter. Trek Financial LLC now owns 5,184 shares of the medical research company’s stock valued at $1,615,000 after buying an additional 1,045 shares in the last quarter. Linden Thomas Advisory Services LLC boosted its stake in shares of Amgen by 0.7% in the first quarter. Linden Thomas Advisory Services LLC now owns 7,115 shares of the medical research company’s stock valued at $2,217,000 after buying an additional 52 shares during the period. Finally, Chemung Canal Trust Co. grew its position in Amgen by 4.1% during the first quarter. Chemung Canal Trust Co. now owns 6,414 shares of the medical research company’s stock worth $1,998,000 after buying an additional 253 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares of the company’s stock, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on AMGN shares. UBS Group decreased their price target on Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Piper Sandler reissued an “overweight” rating on shares of Amgen in a report on Wednesday. Weiss Ratings raised shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Raymond James Financial initiated coverage on shares of Amgen in a research note on Wednesday, September 3rd. They issued a “market perform” rating for the company. Finally, Bank of America boosted their target price on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research note on Friday, September 26th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $307.33.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $319.86 on Thursday. The company has a market capitalization of $172.20 billion, a P/E ratio of 26.15, a price-to-earnings-growth ratio of 2.61 and a beta of 0.45. The company’s 50-day moving average is $288.69 and its 200 day moving average is $287.99. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $335.88.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. During the same period in the previous year, the company earned $5.58 earnings per share. The company’s quarterly revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, November 21st. Amgen’s dividend payout ratio is currently 73.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.